protein and low carbohydrate diets long-term because it would have maximized gluconeogenesis and thereby redirected glucose away from muscles, facilitating the preferential utilization of glucose by the brain, fetus and mammary gland.º I will put off debating physiology with them for another day, but simply indicate in this context that they seem to agree with me that the goal was to prevent glucose from being used by muscle for energy, i. e. muscle insulin resistance was the survival trait. Thus, as far as I can tell, the only difference between the position I formulated and the view expressed in the letter by Drs. Cordain, Brand-Miller, and Mann, is the reason why insulin resistance was of evolutionary value. They argue that insulin resistance did not emerge because of the threat of starvation, but rather because it would have survival value for populations consuming a ªhigh meat, low plant foodº diet. I don't think a great deal would be gained by continued debate over whether the evolutionary pressure that led to the emergence of insulin resistance as a useful survival feature was secondary to periods of inadequate nutrition, as compared with the consistent consumption of high protein, low carbohydrate diets. On the other hand, it would be a step forward if there were general agreement as to the fact that insulin resistance was once evolutionary useful and that explains why the health-related risks of this abnormality are so pervasive now. If Drs. Cordain, Brand-Miller, and Mann agree that insulin resistance was the genotype that Neel initially proposed as providing survival value, I am quite willing to welcome them to the ranks. We think it important to point out that although there is some evidence that IFN a might prevent diabetes in animal models of the disease [2] , there is also evidence to the contrary [3] . At present IFN a cannot be regarded as effective in preventing diabetes in humans, in fact as present knowledge stands it is quite the opposite. It has been suggested that IFN a could induce [4] or accelerate [5] autoimmune reactivity against pancreatic beta cells. A number of patients developed insulin-dependent diabetes whilst receiving IFN a as a treatment for hepatitis [6±8] . It is surprising that Brod et al. made no mention of these papers. Furthermore giving IFN a ªduring vulnerable periodsº, given the present evidence, is likely to make diabetes development more, rather than less, certain [9] . It is acknowledged that the method of administration may make a difference to the action of IFN a but in any case we would conclude with the suggestion that much more work is required to elucidate the role of IFN a in human Type I diabetes, and it is misleading to say that therapy with IFN a is a potentially non-toxic and effective treatment for Type I diabetes.
Yours sincerely, P. E. Beales, P. Pozzilli
